N(%) or Median (25th–75th) | |||||
---|---|---|---|---|---|
All (N = 167) | No Reoccurrence of Arthritis (N = 112) | Arthritis Reoccurrence (N = 55) | P-value* | SMD | |
Joint swelling | |||||
> 1 (vs 0) | 161 (96%) | 109 (97%) | 52 (95%) | 0.40 | 0.14 |
Joint tenderness | |||||
> 1 (vs 0) | 30 (18%) | 20 (18%) | 10 (18%) | 0.96 | 0.01 |
Joint limited range of motion | |||||
> 1 (vs 0) | 95 (57%) | 66 (59%) | 29 (53%) | 0.45 | 0.13 |
Total joints active | 0.99 | 0.21 | |||
1 | 90 (54%) | 59 (53%) | 31 (56%) | ||
2 | 58 (35%) | 39 (35%) | 19 (35%) | ||
3 | 13 (8%) | 9 (8%) | 4 (7%) | ||
4 | 4 (2%) | 3 (3%) | 1 (2%) | ||
5 | 0 | 2 (2%) | 0 | ||
6 | 2 (1%) | ||||
2+ Joints Active (vs 1 only) | 77 (46%) | 53 (47%) | 24 (44%) | 0.65 | 0.07 |
Pain Assessment (1–10)a | 1 (0–4) | 1.5 (0–4.0) | 1 (0–3) | 0.88 | 0.03 |
CHAQ Scoreb | 0.125 (0–0.50) | 0.125 (0–0.500) | 0 (0–0.313) | 0.07 | 0.45 |
MD Global Scorec | 1(1–2) | 2 (1–2) | 1 (1–2) | 0.11 | 0.36 |
ANA status–Positive | 108 (66%) | 68 (62%) | 40 (74%) | 0.12 | 0.26 |
RF status– Positive | 4 (3%) | 4 (4%) | 0 | 0.30 | 0.29 |
HLA-B27 status–Positive | 14 (13%) | 7 (11%) | 7 (17%) | 0.36 | 0.18 |
ESRd | 14 (8–23) | 12 (8–20) | 16 (8–26) | 0.40 | 0.16 |
On injection DMARDs | 29 (17%) | 19 (17%) | 10 (18%) | 0.85 | 0.03 |
On injection biologics | 7 (4%) | 6 (5%) | 1 (2%) | 0.43 | 0.19 |
On NSAIDs | 109 (65%) | 71 (63%) | 38 (69%) | 0.47 | 0.12 |
Total joints injected | 0.87 | 0.03 | |||
2+ | 53 (32%) | 36 (32%) | 17 (31%) | ||
1 | 114 (68%) | 76 (68%) | 38 (69%) | ||
Steroid injection - Aristopan (vs. Kenalog) | 156 (94%) | 107 (96%) | 49 (89%) | 0.08 | 0.24 |
Knee injection dose (mg) | 10 (2–20) | 10 (2–20) | 10 (2–20) | 0.33 | 0.16 |
Knee injection dose (mg/kg)d | 0.33 (0.10–0.78) | 0.40 (0.10–0.77) | 0.19 (0.10–0.84) | 0.50 | 0.12 |